1. Incidence and Outcomes of Pericardial Effusion and Cardiac Tamponade Following Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation
- Author
-
Samir R. Kapadia, Grant W. Reed, Walid Saliba, Rishi Puri, Amar Krishnaswamy, Ankur Kalra, and Agam Bansal
- Subjects
Male ,medicine.medical_specialty ,Percutaneous ,Pericardial effusion ,Pericardial Effusion ,Transcatheter Aortic Valve Replacement ,Postoperative Complications ,Risk Factors ,Cardiac tamponade ,Internal medicine ,medicine ,Humans ,Hospital Mortality ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Incidence ,Incidence (epidemiology) ,Cardiac Pacing, Artificial ,Pericardial cavity ,Aortic Valve Stenosis ,Odds ratio ,Prognosis ,medicine.disease ,United States ,Cardiac Tamponade ,Cardiology ,Female ,Tamponade ,Permanent pacemaker ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Permanent pacemaker (PPM) implantation is required in 5% to 10% of patients following transcatheter aortic valve implantation (TAVI). However, there are limited data on the impact of PPM implantation on the incidence of pericardial effusion, cardiac tamponade, and outcomes after TAVI. We identified all hospitalizations in patients ≥18 years of age who underwent TAVI in the years 2016 to 2017 in the Nationwide Readmission Database. The endpoints of the study were pericardial effusion, cardiac tamponade, and percutaneous or surgical drainage of the pericardial cavity in patients that required PPM implantation after TAVI. Multivariable logistic regression determined associations of PPM implantation, pericardial effusion, and tamponade with patient outcomes. A total of 54,317 unweighted hospitalizations for TAVI were identified, of which 5,639 (10.4%) required PPM. The risk of pericardial effusion was significantly greater in patients who required PPM (2.4% vs 1.6%, adjusted odds ratio (aOR) 1.39 (1.15 to 1.70), p
- Published
- 2021
- Full Text
- View/download PDF